Kraig Biocraft Laboratories Begins Scale up of Second Generation Dragon Silk

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (Company), the leading developer of spider silk based fibers, announces today that it has begun the scale up of its recently announced second generation Dragon Silk.

Consistent with the Companys history of creating performance driven recombinant spider silk, this new material was specially designed at Kraig Labs Michigan research headquarters for application in protective textiles, where increased strength and decreased flexibility are expected to provide improved protection.

Scale up of Dragon Silk 2.0 is well underway, with the production team already raising tens of thousands of the new transgenic silkworms at the Companys US based pilot production facility. Over the next 30 days, Kraig Labs anticipates scaling up production volumes of this new silkworm strain into the millions, as it prepares to create the first silk threads and fabrics made of this next generation recombinant spider silk.

Further, the Company is laying the groundwork to partner with experts in multicomponent thread design and spinning, to develop new specialty threads blending the performance spider silk with other traditional materials. This work is expected to develop threads and fabrics focused specifically on products for the performance wear and other closely linked market segments.

 Stay Updated To Save Money & Time. Join Our Free Newsletter 
. Indepth Analysis & Opinion       . Interviews      . Exclusive Reports  
. Free Digital Magazines      News & updates      . Event Invitations 
                     
& Much More Delivered To Your Inbox For Free.
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

 

The ability to rapidly scale up this newly announced material, from initial testing to pilot scale production, is a major differentiator in our approach, which utilizes silkworms and the existing global silk infrastructure, said COO, Jon Rice. The current global infrastructure, equipment and skilled labor, is able to produce more than 150,000 metric tons of conventional silk per year. Our recombinant spider silk silkworm technology is a direct drop-in replacement for traditional silkworms and allows us to move quickly, with minimal investment, to bring new products to market.

Future scale up of Dragon Silk 2.0, as well as the Companys other lines of recombinant spider silk silkworms, is expected to be transferred to the Companys subsidiary Prodigy Textiles and its operations in Vietnam, while the Companys US facility remains focused on the development of next generation materials.

To view the most recent edition of Kraigs Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Companys future and expectations other than historical facts are forward-looking statements. These statements are made on the basis of managements current views and assumptions. As a result, there can be no assurance that managements expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as believes, plans, expects, anticipates, foresees, estimated, hopes, if, develops, researching, research, pilot, potential, could or other words or phrases of similar import. Forward looking statements include descriptions of the Companys business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Hansel Capital, LLC
Ben Hansel, 720-288-8495
[email protected]

 Stay Updated To Save Money & Time. Join Our Free Newsletter 
. Indepth Analysis & Opinion       . Interviews      . Exclusive Reports  
. Free Digital Magazines      News & updates      . Event Invitations 
                     
& Much More Delivered To Your Inbox For Free.
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

 
Close
Stay Updated To Save Money & Time. Join Our Free Newsletter. 
. Indepth Analysis & Opinion       Interviews          . Exclusive Reports 
. Free Digital Magazines        . News & updates        . Event Invitations
& Much More Delivered To Your Inbox For Free. 
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.
 
Close